The Biospecimen and Pathology Core ofthe Breast SPORE is responsible for accessioning and processing new biospecimens for the Breast SPORE Biospecimen Repository and to make those specimens available for use in the four SPORE main projects and very likely for the Developmental Research and Career Development Programs. Biospecimens will also be made available to other intra- and extra-mural investigators engaged in breast cancer translational research. Requests for biospecimens will be taken under consideration by the Breast SPORE Operations Committee, with a heavy emphasis on scientific merit and on availability of specimens and their associated data needed for analysis. Input from the Biostatistics and Patient Registry Core is included in the evaluation of requests for tissues. The Pathology Team of the Biospecimen Core will provide detailed annotations in the Breast Pathology Database for frozen and formalin-fixed paraffin-embedded tissues from selected cohorts of patients to support SPORE projects and additional projects for which the Breast Biospecimen Repository has provided tissues. The Core pathology team will also interpret IHC staining. The Biospecimen and Pathology Core will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing Shared Resource to process blood samples to provide genomic DNA and serum aliquots, and with the Tissue and Cell Molecular Analysis Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray construction, and digital imaging. Working closely with existing infrastructure such as these shared resources minimizes redundancy of services and utilizes existing experience and state ofthe art equipment. New immunostaining assays will be developed by the Biospecimen and Pathology Core, as well as construction of cell line tissue microarrays to screen and test antibodies for immunostaining formalin-fixed, paraffin-embedded tissues.

Public Health Relevance

The Biospecimen and Pathology Core provides the biospecimens (frozen tissue, FFPE tissue, tissue microarrays and cell line microarrays, blood, serum, DNA, and RNA), pathology annotations, histological services, and pathology support necessary to support the projects of the Mayo Clinic Breast Cancer SPORE as well as other breast cancer translational research projects. The Core also provides histology-related services, such as sectioning, immunostaining, antibody optimization and characterization, and digital imaging. Core pathologists provide IHC interpretations. These functions are essential to most translational research, including the specific projects included in this SPORE proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-09
Application #
8757109
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$316,236
Indirect Cost
$80,207
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guidugli, Lucia; Shimelis, Hermela; Masica, David L et al. (2018) Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. Am J Hum Genet 102:233-248
Kurmi, Kiran; Hitosugi, Sadae; Wiese, Elizabeth K et al. (2018) Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. Cell Rep 22:1365-1373
Goetz, Matthew P; Sangkuhl, Katrin; Guchelaar, Henk-Jan et al. (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther 103:770-777
Baheti, Saurabh; Tang, Xiaojia; O'Brien, Daniel R et al. (2018) HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data. BMC Bioinformatics 19:271
Hart, Steven N; Hoskin, Tanya; Shimelis, Hermela et al. (2018) Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genet Med :
Ho, Ming-Fen; Correia, Cristina; Ingle, James N et al. (2018) Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochem Pharmacol 152:279-292
Yang, Yuzhe; Chan, Jie Ying; Temiz, Nuri A et al. (2018) Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. Horm Cancer 9:371-382
Ingle, James N; Kalari, Krishna R; Wickerham, Donald Lawrence et al. (2018) Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenet Genomics 28:147-152
Abubakar, Mustapha; Chang-Claude, Jenny; Ali, H Raza et al. (2018) Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. Int J Cancer 143:746-757
Leontovich, Alexey A; Jalalirad, Mohammad; Salisbury, Jeffrey L et al. (2018) NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Res 20:105

Showing the most recent 10 out of 473 publications